Close

Macrogenics (MGNX) Says Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at ASCO Gastrointestinal Cancers Symposium

January 18, 2018 2:02 PM EST Send to a Friend
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login